Zosano Pharma, Inc.
34790 Ardentech Court
103 articles with Zosano Pharma, Inc.
Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018, as well as recent business highlights.
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Zosano Pharma Corporation today announced a manufacturing and supply agreement for M207 with a leading global contract development and manufacturing organization, which serves more than 400 clients in the pharmaceutical and biotechnology sectors.
The Company will effect a reverse stock split of its issued and outstanding common stock at an exchange ratio of 1-for-20, at 5:00 p.m. Eastern Time on Thursday, January 25, 2018
Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine
Issuance will extend patent life of M207 to 2037.
Following up on Mr. Steel's resignation, the number of Board of Director seats has been reduced to five.
Zosano reported a net loss for the third quarter of 2017 of $7.9 million.
Zosano Pharma Announces Initiation of Long-Term Safety Study for M207 as an Acute Treatment of Migraine
M207-ADAM is an open label study evaluating the safety of the 3.8mg dose of zolmitriptan in migraine patients who have historically experienced at least 2 migraines per month.
Zosano Pharma to Host Conference Call on Third Quarter 2017 Financial Results and Provide Operational Update
The Company will announce its financial results for this period in a press release to be issued prior to the call.
Zosano Announces Publication Of Pivotal Data Of ADAM Zolmitriptan For The Acute Treatment Of Migraine In Cephalalgia
Zosano Announces U.S. Patent Office Publication Of “Method Of Rapidly Achieving Therapeutic Concentrations Of Triptans For Treatment Of Migraines”
Zosano To Host Conference Call On Second Quarter 2017 Financial Results And Provide Operational Update
Zosano Announces Publication F Positive Phase I Data Of Zolmitriptan Delivery In Future Medicine’s Pain Management Journal
Zosano Presents Additional Data From ZOTRIP Study At American Headache Society, Demonstrating Positive Results For Pain Freedom And Sustained Pain Freedom
ZosanoTo Host Conference Call On First Quarter 2017 Financial Results And Provide Operational Update
Zosano Announces Closing Of Public Offering Of Common Stock And Exercise Of Underwriters’ Over-Allotment Option